Bile acids: Regulation of Synthesis

John Y. L. Chiang*

Department of Integrative Medical Sciences, Northeastern Ohio Univ’s Colleges of Medicine and Pharmacy, Rootstown, OH 44272

Running title: Regulation of bile acid synthesis

Supplemental keywords: CYP7A1, nuclear receptors, FXR, FGF19, cell signaling, lipid metabolism, cholesterol 7α-hydroxylase, drug therapy, cholestasis, liver diseases

*To whom correspondence should be addressed to:

John Y. L. Chiang

Department of Integrative Medical Sciences, Northeastern Ohio Univ’s Colleges of Medicine and Pharmacy, Rootstown, OH 44272

Phone: 330-325-6694

Fax: 330-325-5910

e-mail: jchiang@neoucom.edu
Abstract

Bile acids are physiological detergents that generate bile flow and facilitate intestinal absorption and transport of lipids, nutrients and vitamins. Bile acids also are signaling molecules and inflammatory agents that rapidly activate nuclear receptors and cell signaling pathways that regulate lipid, glucose and energy metabolism. The enterohepatic circulation of bile acids exerts important physiological functions not only in feedback inhibition of bile acid synthesis but also in control of whole body lipid homeostasis. A plethora of bile acid research in recent years has uncovered two novel mechanisms for bile acid inhibition of bile acid synthesis. In the liver bile acids activate a nuclear receptor, farnesoid X receptor (FXR) that induces an atypical nuclear receptor small heterodimer partner (SHP), which subsequently inhibits nuclear receptors, liver related homologue-1 (LRH-1) and hepatocyte nuclear factor 4α (HNF4α), and results in inhibiting transcription of the critical regulatory gene in bile acid synthesis, cholesterol 7α-hydroxylase (CYP7A1). In the intestine FXR induces an intestinal hormone, fibroblast growth factor 15 (FGF15) (or FGF19 in human), which activates hepatic FGF receptor 4 (FGFR4) signaling to inhibit bile acid synthesis. However, the mechanism by which FXR/FGF19/FGFR4 signaling inhibits CYP7A1 remains unknown. In vitro studies using primary human hepatocytes and liver samples from patients with intrahepatic cholestasis show that bile acids induce FGF19 in hepatocytes and the FGF19 autocrine pathway may exist in the human livers. Bile acids and bile acid receptors are therapeutic targets for development of drugs for treatment of cholestatic liver diseases, fatty liver diseases, diabetes, obesity and metabolic syndrome.
Introduction

Since the last special review of cholesterol 7α-hydroxylase (CYP7A1) published in the Journal of Lipid Research in 1977 (1), there has been remarkable progress on the molecular mechanisms of regulation of bile acid synthesis. The cloning of the key regulatory gene CYP7A1 about twenty years ago (2-4), followed by the identification of the bile acid-activated receptor FXR (NR1H4) ten years later (5-7), has generated high interest in bile acid research. New functions of bile acids in metabolic regulation have been unraveled. It is now well recognized that bile acids are important signaling molecules that coordinately regulate a network of metabolic pathways including lipid, glucose, drug, and energy metabolism [Review in (8-15)].

The enterohepatic circulation of bile acids serves as an important physiological route not only for recycling of bile acids and absorption of nutrients but also for regulation of whole body lipid metabolism. However, the mechanism underlying this remarkably efficient and complex physiological process has only recently been unraveled. This review will provide an update on the current understanding of the molecular mechanism of regulation of bile acid synthesis, with a focus on the most critical regulatory gene in the pathway, CYP7A1.

It should be emphasized that the bile acid pool in mice consists mostly of hydrophilic bile acids, muricholic acids and cholic acid, and is very different from the hydrophobic bile acid pool consisting predominantly chenodeoxycholic acid (CDCA), cholic acid (CA) and deoxycholic acid (DCA) in humans. Hydrophobic, but not
hydrophilic bile acids are efficacious endogenous ligands of the nuclear receptors FXR (NR1H4), pregnane X receptor (PXR, NR1I2) and vitamin D receptor (VDR, NR1I1) that play critical roles in the regulation of bile acid synthesis and metabolism. Therefore, results from studying bile acid synthesis in the mouse models may not be extrapolated to humans without verification in suitable human models. This review will focus on the regulation of bile acid synthesis in human livers and will address the species differences in regulation.

**BILE ACIDS ARE VERSATILE SIGNALING MOLECULES**

Bile acids are derived from cholesterol. Bile acid synthesis is the predominant metabolic pathway for catabolism of cholesterol in humans. Hydroxylation and modification of cholesterol to bile acids converts a hydrophobic membrane constituent to amphipathic molecules that can serve as powerful physiological detergents for absorption and transport of nutrients, fats and vitamins, but also as the versatile signaling molecules that are specific ligands for activation of nuclear and membrane receptors. Both free and conjugated-bile acids bind to the ligand-binding domain of FXR, which forms a heterodimer with retinoid X receptor (RXR) and binds to the inverted repeat of AGGTCA-like sequence with one nucleotide spacing (IR1) located in the promoters of the FXR target genes to stimulate gene transcription (5, 16, 17). FXR plays a central role in the regulation of bile acid synthesis, excretion and transport (18, 19), and lipid, glucose and energy metabolism (10, 12, 13, 20, 21). The hydrophobic bile acid CDCA is the most efficacious endogenous FXR ligand, whereas hydrophilic bile acids such as ursodeoxycholic acid and muricholic acids do not activate FXR. Bile acids also bind and
activate PXR (22) and VDR (23). These two receptors play important roles in detoxification of bile acids, drugs, and xenobiotics (22, 24, 25).

Bile acids have been shown to modulate cellular signaling pathways including calcium mobilization, cyclic AMP synthesis and protein kinase C activation (9). It has been reported that bile acids activate the protein kinase C/JNK pathway (26). Bile acids stimulate secretion of pro-inflammatory cytokines, tumor necrosis factor α (TNFα) and interleukin-1β (IL-1β) from Kupffer cells (resident macrophages in hepatocytes) that activate TNF receptor (TNFR) signaling and the mitogen-activated protein kinase (MAPK)/JNK pathway (27, 28). Conjugated bile acids induce mitochondrial reactive oxidizing species, which activates the epidermal growth factor receptor and Raf-1/MEK/ERK signaling pathway (29, 30). Conjugated bile acids activate the ERK and PI3K/AKT pathways via a pertussis toxin-sensitive mechanism involving Gαi protein-coupled receptor (GPCR) (31, 32). Deoxycholic acid activates the FAS receptor and the JNK pathway by induction of acidic sphingomyelinase-generated ceramide in rat primary hepatocytes (33). Bile acids also stimulate insulin receptor signaling (34). In brown adipose tissue, bile acids activate TGR5, a GPCR (35, 36). TGR5 stimulates production of cAMP, which induces iodothyronine deiodinase (D2) and production of thyroid hormone T3 leading to stimulation of energy metabolism and improving glucose tolerance and insulin sensitivity (10, 12, 37). TGR5 is not expressed in hepatocytes but has been localized in the sinusoid endothelial cells (38). In the enteroendocrine cells, TGR5 stimulates glucagon-like peptide 1 (GLP-1) (39), which has anti-diabetic activity.
The liver is the only organ that has all 14 enzymes required for \textit{de novo} synthesis of two primary bile acids in humans, cholic acid (CA, 3\(\alpha\), 7\(\alpha\), 12\(\alpha\)-trihydroxy-cholanoic acid) and chenodeoxycholic acid (CDCA, 3\(\alpha\), 7\(\alpha\)-dihydroxy-cholanoic acid) (Fig 1) (40). The classic bile acid biosynthetic pathway is initiated by CYP7A1 (41). Sterol 12\(\alpha\)-hydroxylase (CYP8B1) is required for synthesis of CA. Mitochondrial sterol 27-hydroxylase (CYP27A1) catalyzes sterol side chain oxidation, after which cleavage of a three-carbon unit in the peroxisomes leads to formation of a C24 bile acid. An alternative (acidic) pathway is initiated by CYP27A1, which in addition to the liver is expressed in macrophages and most other tissues, and may contribute significantly to total bile acid synthesis. Other minor pathways initiated by 25-hydroxylase in the liver and 24-hydroxylase in the brain also may contribute to bile acid synthesis. A non-specific 7\(\alpha\)-hydroxylase (CYP7B1) expressed in all tissues is involved in the generation of oxidized metabolites (oxysterols), which may be transported to the liver and converted to CDCA. Most bile acids are conjugated to glycine or taurine to decrease toxicity and increase solubility for secretion into bile. Bile acid: CoA synthase (BACS) and bile acid: amino acid transferase (BAT) are involved in amino acid conjugation of bile acids. In the intestine, Glyco- and tauro-conjugated CA and CDCA are de-conjugated and 7\(\alpha\)-dehydroxylase activity in bacteria flora removes a 7\(\alpha\)-hydroxy group to form secondary bile acids, deoxycholic acid (DCA, 3\(\alpha\), 12-dihydroxy) and lithocholic acid (LCA, 3\(\alpha\)-monohydroxy), respectively. CA, CDCA and DCA are reabsorbed in the intestine and transported back to the liver to inhibit bile acid synthesis. Most of the LCA is excreted in feces. Small amount of LCA circulated to the liver is sulfo-conjugated at the 3-hydroxy-position by sulfotransferase (SULT2A1) and rapidly secreted into bile. Sulfation is the
major pathway for detoxification of extremely hydrophobic bile acids in humans (42). Details of bile acid chemistry, biology, physiology, and synthesis have been reviewed recently (43, 44).

Regulation of the rate-limiting enzyme in bile acid biosynthetic pathways CYP7A1 has been studied extensively. The CYP7A1 mRNA transcripts in the 3’-untranslated region (3’-UTR) are unusually long (3), and have a very short half-life of about 30 min (45, 46). It has been reported that bile acids reduce CYP7A1 mRNA stability via the bile acid response elements located in the 3’-untranslated region (3’-UTR) (46, 47). Numerous studies have demonstrated that bile acids, steroid hormones, inflammatory cytokines, insulin and growth factors inhibit CYP7A1 transcription through the 5’-upstream region of the promoter (48-53).

Analysis of the proximal promoter of the rat Cyp7a1 identified two regions (footprints) that are putative binding sites for nuclear receptors (54), which are ligand-activated transcription factors that play important roles in embryogenesis, development, and metabolism (18). The sequence located at -73 to -55 of the rat CYP7A1 promoter is highly conserved and was identified as a putative bile acid response element (BARE-I) that might be involved in conferring bile acid inhibition. This sequence contains a DR4 (direct repeat spaced by 4 nucleotides) motif in all species except the human, which binds liver X receptor (LXRα or NR1H3), an oxysterol-activated nuclear receptor. The CYP7A1 is the first LXRα target gene identified (55, 56). This has been confirmed by the finding that when fed a high cholesterol diet, bile acid synthesis increases in wild type mice, but not in Lxrα null mice, which accumulate high levels of cholesterol in the liver (57). In contrast, the human CYP7A1 promoter does not bind LXRα and is not induced
by LXRα due to alteration of the DR4 motif in the BARE-I sequence (58). This has been confirmed by the finding that transgenic mice carrying a human CYP7A1 do not respond to a high cholesterol diet and that the transgene is not induced and bile acid synthesis is not stimulated in these mice (59, 60). Another bile acid response element (BARE-II) is located in a region from -149 to -118 of the rat Cyp7a1 promoter, which has a 18-nucleotide sequence that is completely conserved in many species (61). This sequence contains a DR1 motif, which binds hepatocyte nuclear factor 4α (HNF4α, NR2A1). HNF4α trans-activates CYP7A1 promoter activity by interacting with a co-activator, peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α). Mutation of the DR1 sequence drastically reduced basal CYP7A1 promoter activity and its response to bile acid inhibition (48).

Several earlier studies report that bile acid pool size increases in diabetic rats and insulin inhibits CYP7A1 and CYP8B1 activities [Review in (41)]. Recent studies show that insulin-regulated transcription factor FoxO1 binds to an insulin response sequence in the rat Cyp7a1 promoter and induces rat Cyp7a1 transcription (50). Insulin signaling phosphorylates FoxO1, which is excluded from the nucleus, and results in inhibiting rat CYP7A1. However, the FoxO1 binding site is not present in the human CYP7A1 promoter and FoxO1 functions as a repressor that inhibits HNF4α and PGC-1α activation of the human CYP7A1 (50). In this study, insulin at the physiological concentrations rapidly stimulates CYP7A1 expression by inhibiting FoxO1, while high concentrations of insulin found in the insulin resistance state activate steroid response element binding protein-1c (SREBP-1c), which inhibits CYP7A1 expression by interacting with HNF4α. On the other hand, glucagon and cAMP strongly inhibit CYP7A1 expression via
activation of PKA, which phosphorylates HNF4α and abolishes HNF4α DNA-binding activity, and resulting in inhibition of CYP7A1 expression in human hepatocytes (51). This is in contrast to other studies in mice that cAMP and fasting induces Cyp7a1 expression, which parallels the induction of PGC-1α and phosphoenolpyruvate carboxykinase (PEPCK) (62, 63). These investigators suggest that Cyp7a1 expression and bile acid synthesis is up regulated during fasting and there is a coordinated regulation of bile acid synthesis and gluconeogenesis by the fasting-to-fed cycle. Biosynthetic pathways should be inactivated during fasting to conserve energy, except glucogeneogenesis, which provides energy during starvation. The induction of Cyp7a1 in fasting response in mice is in contrast to the observation in human patients that the serum 7α-hydroxy-4-cholesten-3-one (C4), a serum marker for bile acid synthesis and CYP7A1 enzyme activity, is reduced during the fasting, and increased during the post-prandial state, and gradually decreased during the post-absorptive state (64). In addition, bile acid synthesis increases in the morning regardless of food intakes (65).

FXR plays a critical role in the regulation of bile acid synthesis and homeostasis (66). However, FXR inhibits CYP7A1 (67), CYP8B1 (68) and CYP27A1 (69) transcription by complicated mechanisms described later. A recent study identified an FXR-binding site in the human but not mouse CYP8B1 promoter suggesting a species-specific regulation of bile acid synthesis by FXR (70). A transcriptional repressor GPS2 differentially regulates CYP7A1 and CYP8B1 transcription by interacting with SHP, liver related homologue-1 (LRH-1, or human α-fetoprotein transcription factor, FTF, NR5A2), FXR, and HNF4α bound to these two promoters. In the CYP7A1 and CYP8B1 promoters, the HNF4α binding site overlaps with a binding site for LRH-1. The promoter of the
human CYP27A1 also has an HNF4α binding site (69). FXR stimulates bile acid conjugation by inducing the genes encoding BACS and BAT, which also are induced by HNF4α (71). Thus, FXR and HNF4α may coordinately regulate bile acid synthesis and conjugation.

It has been reported that PPARα plays a role in the regulation of bile acid synthesis (72). Bile acids induce PPARα transcription via induction of FXR (73). PPARα inhibits human CYP7A1 transcription by inhibiting HNF4α transactivation activity (74). PPARα also regulates CYP27A1 expression in macrophages (75). Activation of PPARα has been shown to increase un-conjugated bile acids by induction of peroxisomal bile acid thioesterase (76), indicating that PPARα may play a role in balancing the amount of conjugated and free bile acids.

Orphan nuclear receptor Rev-erbα plays a role in the regulation of bile acid synthesis (77). Rev-ERbα is a clock gene involved in the control of circadian rhythmicity (78-80). The activity of Rev-erbα is activated by heme (81) and functions as a heme sensor and transcriptional repressor that regulates lipid metabolism and adipogenesis (82, 83). Rev-erbα may coordinate energy metabolism and circadian rhythm during feeding and starvation (84). It has been well documented that CYP7A1 and CYP8B1 expression exhibits a pronounced diurnal rhythm in both 12 hr light: 12 hr dark cycle and constant darkness (85-88). In humans bile acid synthesis exhibits a diurnal rhythm with two peaks around 3 pm and 9 pm. CYP7A1 expression is induced by diurnal regulated D-site binding protein (DBP) (89-92) and Rev-erbα (93), but repressed by the clock genes, DEC2, and E4BP4 (93, 94). These authors conclude that the circadian rhythm of Cyp7a1 is regulated directly by DBP, DEC2 and Rev-erbα/β. However, in Rev-erbα knockout
mice, Cyp7a1 expression is induced and bile acid synthesis is stimulated, but the diurnal rhythm of Cyp7a1 remains (77). These authors suggest that Rev-erbα does not regulate the diurnal rhythm of CYP7A1 but induces CYP7A1 by inhibiting SHP and E4BP4 expression (77). In contrast, Rev-erbα does not regulate the circadian rhythm of CYP8B1.

**FXR REGULATION OF ENTEROHEPATIC CIRCULATION OF BILE ACIDS**

In humans, about 0.2-0.6 g of bile acids are synthesized daily in human liver. The enterohepatic circulation of bile acids is illustrated in Fig 2. Conjugated bile acids are secreted into bile by canalicular bile salt export pump (BSEP, ABCB11) and stored in the gallbladder. Bile acids are spilled over into sinusoid blood when concentrations increase in the hepatocytes. Bile acids in blood circulation are reabsorbed when passing through the renal tubules in the kidney and are circulated back to the liver through systemic circulation. Some bile acids secreted in the bile duct are reabsorbed in the cholangiocytes and recycled back to hepatocytes (the cholangiohepatic shunt). After each meal, gallbladder contraction empties bile acids into the intestinal tract. When passing through the intestinal tract, some bile acids are reabsorbed in the upper intestine by passive diffusion but most bile acids (95%) are reabsorbed in the ileum by apical sodium-dependent bile acid transporter (ASBT) located in the brush border membrane. Bile acids are trans-diffused across the enterocyte to the basolateral membrane where the organic solute transporter α and β heterodimer (OSTα/OSTβ) effluxes bile acids into portal blood circulation, transported to the sinusoid and taken up by Na⁺-dependent taurocholate co-transport peptide (NTCP) into hepatocytes. In colon, DCA is reabsorbed and recycled
with CA and CDCA to the liver. A bile acid pool of about 3 g is recycled 4 to 12 times a day. Bile acids lost in the feces (0.2-0.6 g/d) are replenished by de novo synthesis in the liver to main a constant bile acid pool.

FXR plays a key role in control of enterohepatic circulation of bile acids (Fig 3). FXR induces the expression of BSEP in the canalicular membrane, which is the driving force for bile formation. A FXR binding site in the human BSEP promoter has been identified (95). Mutation of BSEP causes progressive familial intrahepatic cholestasis type 2 (PFIC) (96, 97). In the intestine, bile acids are reabsorbed into the enterocytes by ASBT in the brush border membrane. Genetic knockout of Asbt in mice interrupts enterohepatic circulation of bile acids and causes bile acid malabsorption (98). FXR induces ASBT expression in mice, inhibits ASBT expression in rabbit, but does not affect ASBT in humans (99). FXR induces the expression of ileal bile acid binding protein (IBABP), which is the first target gene of FXR identified in the gastro-intestine system (100). The physiological function of IBABP is not clear. It may bind bile acids and reduce intracellular bile acid concentrations in the ileum. Bile acids are excreted from enterocytes via OSTα/OSTβ located in the basal lateral (sinusoid) membrane (101, 102). The bile acid pool is reduced in Ostα/Ostβ -/- mice (103, 104). This is a result of increased fibroblast growth factor 15 (FGF15) expression in mouse intestine and reduced Cyp7a1 expression in mouse liver (see below). OST appears to be the major bile acid efflux transporter in the intestine. OSTα/OSTβ also has been localized in the sinusoid membrane of hepatocytes (103). The mouse Ostα/Ostβ promotors have both FXR and LRH-1 binding sites indicating that OSTα/OSTβ expression may be induced by FXR and inhibited by SHP/LRH-1(105). FXR induces the hepatic OSTα/OSTβ expression in
patients with primary biliary cirrhosis and in bile duct-ligated rats and mice (106). The FXR induction of OSTα/OSTβ may be an adaptive response to cholestasis to excrete bile acids from hepatocytes. Bile acids are transported back to hepatocytes via portal blood circulation, taken up by NTCP in the sinusoidal membrane. FXR inhibits Ntcp transcription by SHP-dependent inhibition of RXR/RAR induction of Ntcp (107). Thus, FXR plays a critical role in the coordination of bile acid synthesis, biliary bile acid secretion, intestinal bile acid reabsorption and secretion, and bile acid uptake into hepatocytes. Deficiency in FXR regulation of enterohepatic circulation of bile acids may lead to cholestasis (8, 96, 108, 109).

**MECHANISMS OF FXR INHIBITION OF CYP7A1**

Bile acid synthesis is feedback inhibited by bile acids returning to the liver via enterohepatic circulation to inhibit CYP7A1 (110). Currently there are two FXR-dependent mechanisms for bile acid inhibition of CYP7A1 gene transcription (Fig 3). In the liver FXR induces SHP to inhibit CYP7A1. In the intestine FXR induces FGF19 to activate liver FGF receptor 4 (FGFR4) signaling to inhibit CYP7A1.

**The FXR/SHP pathway**

The FXR binding site is not present in the CYP7A1 promoter (67). Three laboratories independently report a cascade mechanism of FXR inhibition of CYP7A1 (17, 111, 112). They show that FXR induces an atypical orphan nuclear receptor, SHP that has no DNA-binding domain and is a common transcriptional repressor of nuclear receptors. SHP then inhibits the trans-activating activity of LRH-1 and results in
inhibiting CYP7A1 transcription (17, 111, 112). SHP also interacts with HNF4α to block HNF4α interaction with PGC-1α, and results in inhibiting CYP7A1 and CYP8B1 transcription (113, 114). The LRH-1 and HNF4α binding sites overlap in the CYP7A1 and CYP8B1 promoter (113, 114). LRH-1 is a weak transcription factor and may compete with HNF4α for binding to the BARE and results in inhibiting CYP7A1 and CYP8B1 transcription.

The molecular mechanisms of SHP inhibition of gene expression have been studied in transgenic mice overexpressing SHP in hepatocytes (115). SHP transgenic mice have fat accumulation. Global gene expression profiling combined with chromatin immunoprecipitation assay reveals that SHP affects the genes involved in bile acid synthesis (CYP7A1, CYP8B1, CYP7B1), conjugation (BAT) and transport (BSEP, NTCP, MDR2) as expected. Interestingly SHP transgenic mice express lower levels of SR-B1, CYP51b, but higher levels of ABCA1, PPARγ, SREBP-1c, CD36 (Fatty acid transporter), FAS (fatty acid synthase), ACC1 (acyl-CoA carboxylase-1), SCD-1 (stearoyl-CoA desaturase-1) involved in fatty acid metabolism. These data suggest that SHP may play a role in down regulation of lipogenesis and protecting against steatosis. SHP alters chromatin configuration in SHP down regulated genes. Interestingly SHP associates with unmodified and methylated-histone 3-Lys9 (H3K9), but not acetylated-H3K9. Furthermore, SHP interacts with histone deacetylase-1 (HDAC-1) and a histone methytransferase G9a (116) suggesting that SHP repression of gene transcription by multiple steps involving histone deacetylation, followed by H3K9 methylation, and stable association of SHP to chromatin. Another study reports that SHP interacts with a repressor mSin3A and recruits chromatin remodeling complex Swi/Snf/Brm to CYP7A1
chromatin containing the bile acid response elements (117). A follow up study shows that SHP recruits HDACs and interacts with G9a to enhance SHP inhibition of CYP7A1 (118). It has been shown that bile acids stimulate translocation of HDACs to the nucleus to assemble a repressor complex consisting of HDAC7, SHP, and a common nuclear receptor co-repressor silencing mediator of retinoid and thyroid receptor (SMRT) to inhibit CYP7A1 (119). Another nuclear receptor co-repressor GPS2 interacts with SHP, LRH-1, HNF4α and FXR, and differentially regulates CYP7A1 and CYP8B1 (70). It is not clear how bile acids induce or recruit these repressor complexes to inhibit CYP7A1 transcription.

Two recent studies of liver conditional knockout of Lrh-1 in mice show that Cyp8b1 expression is abolished and cholic acid is eliminated, however Cyp7a1 expression is not affected and not repressed by FXR (120, 121). These results suggest that LRH-1 may not be involved in FXR inhibition of CYP7A1, but is required for FXR inhibition of CYP8B1 gene transcription. This is consistent with the earlier finding that knockout of the Shp gene in mice did not prevent bile acid inhibition of CYP7A1 mRNA expression (122, 123). This raises the doubt that the FXR/SHP/LRH-1 pathway is involved in bile acid inhibition of CYP7A1 under normal physiological conditions. It should be noted that bile acid induction of SHP is very rapid and transient. It is likely that SHP is transiently induced by bile acids or inflammatory cytokines in acute phase response to liver injury, cholestasis and during liver regeneration (124) to protect liver against toxicity of bile acids and other metabolites (53, 125).

The FXR/FGF19/FGFR4 pathway
Holt et al (126) first identified the fibroblast growth factor 19 (FGF19) as a FXR target gene by microarray analysis of human primary hepatocytes treated with an FXR agonist GW4064. They report that FGF19 activates receptor tyrosine kinase FGF receptor 4 (FGFR4) signaling to inhibit CYP7A1 mRNA expression levels in hepatocytes (126). A subsequent study has demonstrated that FXR induces FGF15, a mouse ortholog of FGF19 in mouse intestine, and the expression of FGF15 mRNA is inversely correlated to CYP7A1 mRNA expression levels in mouse liver (127). In Fgfr4−/− or Fgf15−/− mice, FGF15 and GW4064 do not affect Cyp7a1 mRNA expression levels, supporting the role of FGF15/FGFR4 signaling in mediating bile acid inhibition of Cyp7a1 expression. These investigators proposed that FGF15 might function as an enterohepatic signaling to regulate bile acid synthesis (Fig 3). Furthermore, GW4064 represses Cyp7a1 in liver-specific Fxr knockout mice, but not in intestine specific Fxr knockout mice unequivocally confirming that the intestinal FXR, but not liver FXR is required for bile acid inhibition of Cyp7a1 gene expression (128). These data also suggest that CYP8B1 is preferentially regulated by the liver FXR/SHP pathway, and not by the FXR/FGF19/FGFR4 pathway. It appears that FGF19 is the bile acid induced “intestinal factor” that is secreted in the ileum to inhibit bile acid synthesis in hepatocytes as proposed by Pandak et al in 1995 (129).

FGF19 activation of FGFR4 signaling requires β-Klotho, a membrane-bound glycosidase co-expressed with FGFR4 in hepatocytes (Fig 3). Genetic ablation of the β-Klotho gene in mice increases bile acid synthesis and secretion, and Cyp7a1 expression (130). However, Cyp8b1 expression was not altered in the β-Klotho knockout mice suggesting differential regulation of Cyp7a1 and Cyp8b1 by β-Klotho. Similar to the β-
Klotho knockout mice, the Fgfr4 deficient mice have the same phenotypes of increased bile acid synthesis (131). Overexpression of a constitutively active human FGFR4 represses Cyp7a1 expression and decreases bile acid pool in wild type mice (132). All these findings support the critical role of FGFR4 signaling in mediating bile acid feedback regulation. FGF19 has been detected in human patient sera. Interestingly, serum FGF19 levels exhibit diurnal variation that peaked 90 to 120 min after a postprandial rise in serum bile acids and serum 7α-hydroxy-4-cholesten-3-one (C4) levels (133). Feeding of CDCA increased FGF19 expression whereas a bile acid-binding resin cholestyramine reduced FGF19 in humans. These results support that FGF19 plays an important role in inhibiting bile acid synthesis in humans. It is likely that the FXR/FGF19/FGFR4 pathway is the physiological mechanism for bile acid feedback regulation of bile acid synthesis.

**THE AUTOCRINE FUNCTIONS OF FGF19**

FGF15 has not been identified in mouse sera and livers, and bile acids do not induce FGF15 expression in mouse liver. Song et al (53) reports recently that bile acids are able to induce FGF19 in primary human hepatocytes. This study shows that CDCA and GW4064 rapidly induce FGF19 mRNA expression, FGF19 protein secretion, and tyrosine phosphorylation of FGFR4, but inhibit CYP7A1 mRNA expression in primary human hepatocytes suggesting that liver produced FGF19 is secreted from hepatocytes to activate FGFR4 signaling in hepatocytes by an autocrine or paracrine mechanism. Furthermore, knockdown of SHP expression by siRNA does not affect FGF19 inhibition of CYP7A1 mRNA expression in primary human hepatocytes suggesting that SHP may
not be required in FGF19 signaling (53). It is also noted that induction of FGF19 is sustained for at least 24 hours but induction of SHP mRNA by CDCA and GW4064 is transient reaching the maximum in 1 to 3 hours and reducing to the basal levels after 6 hours of treatment (53). All these data show a lack of correlation between SHP and CYP7A1 expression levels in FGF19 signaling, in contrast to the inverse relationship between SHP and CYP7A1 expression levels that supports the FXR/SHP pathway. The study by Song et al (53) demonstrates that FGF19/FGFR4 signaling activates and phosphorylates mainly the MAPK/ERK1/2 signaling pathway in human primary hepatocytes (Fig 3). However, the down stream factor(s) of the FGF19 pathway that inhibits CYP7A1 gene transcription remain unknown.

Schaap et al. (134) reports a study of FGF19 expression in patients with extrahepatic cholestasis. These investigators observed a 6 and 8-fold higher plasma FGF19 in cholestatic patients than non-cholestatic patients and post-cholestatic patients receiving a biliary stent to drain bile acids, respectively. FGF19 mRNA could be detected in the majority of liver specimens with a wide range of expression levels, and was 31 to 374-fold higher in the cholestatic group than in the drained and non-cholestatic group, respectively. CYP7A1 mRNA expression levels were 37 and 9.8 fold lower in the cholestatic group than in the control and drained groups, respectively. These investigators reasoned that FGF19 should be decreased in extrahepatic cholestasis patients, if FGF19 is only produced in the intestine. They suggest that bile acids accumulated in cholestatic liver could induce FGF19 expression as an adaptive response to cholestatic liver injury.
FXR-INDEPENDENT BILE ACID INHIBITION OF CYP7A1

There are several FXR-independent mechanisms for bile acid inhibition of CYP7A1 (Fig 4). The secondary bile acid, LCA is a ligand of PXR and VDR. These two receptors bind to the BARE-I sequence in the human CYP7A1 promoter and inhibit CYP7A1 promoter activity (135, 136). PXR interacts with HNF4α and blocks HNF4α recruitment of PGC-1α to CYP7A1 chromatin and results in inhibiting CYP7A1 transcription. Guggulsterone, an FXR antagonist and PXR agonist inhibits CYP7A1 transcription by activating PXR (137). Interestingly, PXR induces CYP27A1 expression in intestinal cells but not in liver cells, suggesting that PXR may play a role in the regulation of ABCA1 efflux of cholesterol from intestine cells to synthesize HDL for reverse transport of cholesterol to the liver (138). It has been reported that the constitutive androstane receptor (CAR) binds to the DR1 motif and competes with HNF4α for co-activators PGC-1α and glucocorticoid receptor interacting protein-1 (GRIP-1), and results in inhibiting CYP7A1 transcription (139). The LCA-activated VDR inhibits CYP7A1 gene transcription by several mechanisms; VDR may interact with HNF4α and blocks HNF4α interaction with PGC-1α; VDR and HNF4α competes for binding to the DR1 motif; VDR competes with HNF4α for co-activators; and VDR recruits co-repressors to the CYP7A1 promoter (136).

During the acute phase response, lipopolysaccharide (LPS) activates the Toll-like receptor 4 (TLR4) to induce and release TNFα and IL-1β from the Kupffer cells. Bile acids also induce TNFα and IL-1β, which may cross the sinusoid membrane to activate the TNF receptor and the MAPK/JNK pathway to inhibit CYP7A1 transcription (27).
JNK phosphorylates cJun and HNF4α, and results in inhibiting CYP7A1 and CYP8B1 transcription and bile acid synthesis (49, 140, 141). TGFβ-1 secreted from Kupffer cells activates TLR4 in hepatic stellate cells (HSC) and secretion of TGFβ-1, which activates its receptor TRβII and the SMAD signaling pathway in hepatocytes. Bile acids stimulate TGFβ-1 expression in hepatocytes by induction of thrombospondin-1, which activates latent TGFβ-1 in HSC leading to the activation of HSC (142). SMAD3 enters the nucleus, recruits HDACs and mSin3A to inhibit HNF4α activation of CYP7A1 transcription (143). TGFβ1 and bile acids activate the Ras/MAPK/JNK pathway, induce reactive oxidative species, and phosphorylate a tumor suppressor p53 (144, 145). It has been reported that p53 interacts with HNF4α and inhibits HNF4α activity (146), and may result in inhibiting CYP7A1. In contrast, TGFβ1 stimulates the rat CYP7A1 promoter, which contains the binding sites for SMAD, FoxO1 and HNF4α. These three transcription factors synergistically induce rat CYP7A1 transcription (147). This may explain the paradoxical induction of CYP7A1 transcription in bile duct-ligated rats (148).

Bile acids also activate epidermal growth factor receptor and the Raf-1/MEK/ERK signaling pathway to inhibit CYP7A1 transcription (29). Bile acids enhance the insulin receptor signaling in rat primary hepatocytes (34). Insulin signaling phosphorylates and activates the insulin receptor leading to activation of insulin receptor substrates, PI3K and AKT, which phosphorylates FoxO1 and inhibits CYP7A1 transcription (50). Bile acid-activated protein kinase C phosphorylates cJun to inhibit CYP7A1 transcription (26). During acute phase response to liver injury and regeneration, hepatocyte growth factor (HGF) released from HSC cells activates the HGF receptor cMet and MAPK pathways to inhibit CYP7A1 transcription and bile acid synthesis (52). All these cell-signaling
pathways may play critical roles in protection against bile acid toxicity during liver injury and cholestasis. All these signaling pathways may converge to regulate CYP7A1 chromatin structure by epigenetic mechanism.

CONCLUSION AND FUTURE PERSPECTIVES

Bile acid research in last two decades has contributed significantly to our understanding of the mechanisms of bile acid synthesis and pathogenesis of liver diseases and metabolic syndrome. The CYP7A1 mRNA expression has become a biomarker for studying lipid metabolism in animal models of fatty liver disease, diabetes, obesity, and cholestasis. The mechanism underlying FXR/FGF19/FGFR4 signaling in inhibition of CYP7A1 transcription and bile acid synthesis remains to be elucidated. The genetically modified mouse models are widely used for studying bile acid synthesis and regulation. However, distinct species-differences in bile acid composition, synthesis and regulation between humans and mice exist. It is imperative that a suitable human model system be developed to verify results from animal studies.

Bile acids and bile acid-activated receptors FXR, PXR, CAR and VDR are therapeutic targets for development of drugs for treatment of gallstone, fatty liver disease, cholestatic liver disease, obesity, diabetes and metabolic syndrome (12, 149, 150). A bile acid derivative, 6α-ethyl-CDCA has a protective effect on cholestasis (151) and is in the second phase of clinical trials for primary biliary cirrhosis. Another bile acid derivative, 6α-ethyl, 23(S)-methyl-CDCA is a selective TGR5 agonist and has therapeutic potential for the treatment of obesity, diabetes, and metabolic syndrome (152). Fatty acid-bile acid conjugates are in clinical trials for treatment of nonalcoholic fatty liver disease (NAFLD)
and nonalcoholic steatohepatitis (NASH), gallstone disease and cardiovascular diseases (153-156). It is anticipated that basic research in bile acid metabolism will be translated into clinical diagnosis and treatment of liver and metabolic diseases in the near future.
Footnotes

Abbreviations: CAR, constitutive androstane receptor; CA, cholic acid; CDCA, chenodeoxycholic acid; CYP7A1, cholesterol 7α-hydroxylase; CYP8B1, sterol 12α-hydroxylase; CYP27A1, sterol 27 hydroxylase; DCA, deoxycholic acid; LCA, lithocholic acid; LXR, liver orphan receptor; FGF19, fibroblast growth factor 19; FGFR4, FGF receptor 4; FXR, farnesoid X receptor; HDAC, histone deacetylase; HNF4α, hepatocyte nuclear factor 4α; LRH-1, liver related homologue-1; MAPK, mitogen-activated protein kinase; PXR, pregnane X receptor; PPARα, peroxisome proliferator activated receptor α; PGC-1α, PPARγ co-activator 1α; SHP, small heterodimer partner; VDR, vitamin D receptor.

Acknowledgement:

This work is supported by NIH grants DK44442 and DK58379.
References:


Figure legends

**Fig 1: Bile acid synthesis.** Cholesterol is converted to two primary bile acids in human liver, cholic acid (CA) and chenodeoxycholic acids (CDCA). Key regulated enzymes, CYP7A1, CYP8B1, CYP27A1, CYP7B1 in the pathways are indicated. CYP7A1 initiates the classic (neutral) bile acid biosynthetic pathway in the liver. CYP27A1 initiates the alternative (acidic) pathway in the liver and macrophages. CA and CDCA are conjugated to glycine (G) and taurine (T). Bile acid CoA synthase (BACS) and bile acid: amino acid transferase (BAT) are two key enzymes involved in amino conjugation of bile acids. In the intestine, conjugated CA and CDCA are de-conjugated and then dehydroxylated at the 7α-position to the secondary bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA), respectively.

**Fig 2: Enterohepatic circulation of bile acid synthesis.** In humans, about 0.2-0.6 g (averaging 0.5 g) bile acids are synthesized daily in human liver. Conjugated bile acids are secreted into bile and stored in the gallbladder. Some bile acids are spilled over into sinusoid blood and reabsorbed when passing through the renal tubules in the kidney and circulated back to the liver through mensenteric and arterial blood flow. Some bile acids secreted in the bile duct are reabsorbed in the cholangiocytes and recycled back to hepatocytes (cholangiohepatic shunt). After each meal, gallbladder contraction empties bile acids into the intestinal tract. When passing through the intestinal tract, some bile acids are reabsorbed in the upper intestine by passive diffusion but most bile acids (95%) are reabsorbed in the ileum. Bile acids are trans-diffused across the enterocyte to the basolateral membrane and excreted into portal blood circulation back to the sinusoid of hepatocytes. In colon, DCA is reabsorbed by passive transport, and recycled with CA and
CDCA to the liver. A bile acid pool of about 3 g is recycled 4 to 12 times a day. Bile acids lost in the feces (0.2-0.6 g/d) are replenished by de novo synthesis in the liver to maintain a constant bile acid pool.

**Fig 3: Mechanisms of FXR regulation of enterohepatic circulation of bile acid.** Bile acids synthesized in the liver are excreted into bile via BSEP, and stored in the gallbladder. After each meal, bile acids are excreted into the intestinal tract. In the ileum, bile acids are reabsorbed by ASBT in the brush border membrane. Bile acids activate FXR to induce IBABP in enterocytes. OSTα/β transporter in the basolateral membrane effluxes bile acids to portal circulation to hepatocytes where they are taken up by NTCP. In the liver, bile acids activate FXR, which induces SHP expression. SHP then inhibits LRH-1 (or human FTF) and HNF4α transactivation of CYP7A1 (**FXR/SHP pathway 1**). In the endocrine pathway, intestinal bile acids activate FXR, which induces FGF19 expression. FGF19 may be transported to the liver to activate a liver-specific receptor tyrosine kinase FGFR4 (**FXR/FGF19/FGFR4 pathway 2**). In the autocrine pathway (**pathway 3**), cholestatic bile acids may activate FXR and FGF19/FGFR4 signaling, which activates the MAPK/ERK1/2 pathway to inhibit CYP7A1 transcription. It is not clear how the FGF19/ERK1/2 pathway down regulates CYP7A1 transcription. The endocrine pathway may be a physiological pathway for bile acid inhibition of bile acid synthesis, while the autocrine pathway may be an adaptive response to protect liver from cholestatic injury. The BARE-II, (bile acid response element-II) contains 18-bp sequence of overlapping HNF4α and FTF (α-fetoprotein transcription factor, a human homologue of mouse LRH-1) binding site, which is completely conserved in all species.
Fig 4: FXR-independent and bile acid-activated cell signaling pathways in regulation of CYP7A1 transcription. (1) LCA activates PXR, CAR (indirectly) and VDR, which inhibit CYP7A1 transcription by interacting with HNF4α and blocking PGC-1α activation of HNF4α. (2) Bile acids stimulate inflammatory cytokines TNFα and IL-1β in Kupffer cells, which activate the TNF receptor and the MAPK/JNK pathways to inhibit CYP7A1 transcription. (3) TGFβ1 secreted from the HSC cells activates TGFβ1 receptor and the MAPK/Smad pathway. Smad3 interacts with HNF4α and recruitment of HDAC and mSin3A to inhibit CYP7A1 transcription. (4) Bile acids and TGFβ1 induce reactive oxidizing species (ROS) and activate p53, which interacts with HNF4α and inhibits HNF4α trans-activation of CYP7A1. (5) Bile acids also activate epidermal growth factor receptor (EGFR) and the Raf-1/MEK/ERK signaling pathway to inhibit CYP7A1. (6) Bile acids enhance the insulin receptor signaling to phosphorylate and activate insulin receptor substrate, PI3K and AKT, which phosphorylates FoxO1 and inhibits CYP7A1. (7) Bile acids also activate protein kinase C, which phosphorylates cJun to inhibit CYP7A1. (8) During liver injury and regeneration, hepatocyte growth factor (HGF) secreted from HSC cells activates the HGF receptor cMet and the MAPK pathways to inhibit CYP7A1. All these signaling pathways may converge to regulate chromatin structure by epigenetic mechanism.
Fig 1

Cholesterol

\[ \xrightarrow{\text{CYP7A1}} \]

\[ \xrightarrow{\text{CYP8B1}} \]

\[ \xrightarrow{\text{CYP27A1}} \]

\[ \xrightarrow{\text{BACS}} \]

\[ \xrightarrow{\text{BAT}} \]

G/T-CA   G/T-CICA

\[ \xrightarrow{\text{DCA}} \]

\[ \xrightarrow{\text{LCA}} \]

CYP27A

CYP7B1
Fig 2

Portal venus return to hepatocytes (95% of biliary secretion)

Biliary Secretion: 3 g in pool x 4-12 cycles/d

Fecal Excretion (0.2 to 0.6 g/d)